LitCovid-sample-Enju  

PMC:7228307 / 58931-59423 JSONTXT 15 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T253 0-11 NN denotes Engineering
T254 12-14 IN denotes of
T255 15-18 DT denotes the
T256 19-23 NN denotes IgG1
T257 24-26 NN denotes Fc
T258 27-33 NN denotes region
T259 34-37 IN denotes for
T260 38-46 VBN denotes enhanced
T261 47-53 CC denotes and/or
T262 54-62 JJ denotes specific
T263 63-70 NN denotes binding
T264 71-73 TO denotes to
T265 74-81 NN denotes FcγRIIb
T266 82-85 MD denotes can
T267 86-93 RB denotes greatly
T268 94-101 VB denotes improve
T269 102-111 JJ denotes agonistic
T270 112-123 NN denotes function.72
T271 123-124 -COMMA- denotes ,
T272 125-128 CD denotes 118
T273 128-129 -COMMA- denotes ,
T274 130-133 CD denotes 119
T275 133-134 -COMMA- denotes ,
T276 135-138 CD denotes 120
T277 139-143 JJ denotes Such
T278 144-153 NNS denotes mutations
T279 154-161 VBD denotes induced
T280 162-175 RB denotes significantly
T281 176-183 JJR denotes greater
T282 184-193 JJ denotes agonistic
T283 194-202 NN denotes activity
T284 203-205 IN denotes in
T285 206-208 DT denotes an
T286 209-217 NN denotes anti‐DR5
T287 218-223 NN denotes model
T288 224-231 IN denotes through
T289 232-241 VBN denotes increased
T290 242-251 NN denotes induction
T291 252-254 IN denotes of
T292 255-264 JJ denotes apoptotic
T293 265-270 NN denotes death
T294 271-274 CC denotes and
T295 275-284 VBD denotes decreased
T296 285-290 NN denotes tumor
T297 291-297 NN denotes growth
T298 298-306 VBN denotes compared
T299 307-311 IN denotes with
T300 312-322 JJ denotes unmodified
T301 323-331 NN denotes IgG1.121
T302 332-335 DT denotes The
T303 336-342 NNP denotes “SELF”
T304 343-356 NNS denotes modifications
T305 357-361 WDT denotes that
T306 362-374 RB denotes dramatically
T307 375-378 CC denotes and
T308 379-390 RB denotes selectively
T309 391-399 VBP denotes increase
T310 400-408 NN denotes affinity
T311 409-412 IN denotes for
T312 413-420 NN denotes FcγRIIb
T313 421-425 VBP denotes have
T314 426-430 RB denotes also
T315 431-435 VBN denotes been
T316 436-440 VBN denotes used
T317 441-443 TO denotes to
T318 444-451 VB denotes enhance
T319 452-458 JJ denotes immune
T320 459-466 NN denotes agonism
T321 467-469 IN denotes in
T322 470-472 DT denotes an
T323 473-482 NN denotes anti‐OX40
T324 483-492 NN denotes model.122
R258 T253 T254 arg1Of Engineering,of
R259 T258 T254 arg2Of region,of
R260 T258 T255 arg1Of region,the
R261 T258 T256 arg1Of region,IgG1
R262 T258 T257 arg1Of region,Fc
R263 T258 T259 arg1Of region,for
R264 T263 T259 arg2Of binding,for
R265 T263 T260 arg1Of binding,enhanced
R266 T260 T261 arg1Of enhanced,and/or
R267 T262 T261 arg2Of specific,and/or
R268 T263 T262 arg1Of binding,specific
R269 T263 T264 arg1Of binding,to
R270 T265 T264 arg2Of FcγRIIb,to
R271 T253 T266 arg1Of Engineering,can
R272 T268 T266 arg2Of improve,can
R273 T268 T267 arg1Of improve,greatly
R274 T253 T268 arg1Of Engineering,improve
R275 T270 T268 arg2Of function.72,improve
R276 T270 T269 arg1Of function.72,agonistic
R277 T270 T271 arg1Of function.72,","
R278 T272 T271 arg2Of 118,","
R279 T270 T273 arg1Of function.72,","
R280 T274 T273 arg2Of 119,","
R281 T268 T275 arg1Of improve,","
R282 T294 T275 arg2Of and,","
R283 T278 T276 arg1Of mutations,120
R284 T278 T277 arg1Of mutations,Such
R285 T278 T279 arg1Of mutations,induced
R286 T283 T279 arg2Of activity,induced
R287 T281 T280 arg1Of greater,significantly
R288 T283 T281 arg1Of activity,greater
R289 T283 T282 arg1Of activity,agonistic
R290 T279 T284 arg1Of induced,in
R291 T287 T284 arg2Of model,in
R292 T287 T285 arg1Of model,an
R293 T287 T286 arg1Of model,anti‐DR5
R294 T279 T288 arg1Of induced,through
R295 T290 T288 arg2Of induction,through
R296 T290 T289 arg2Of induction,increased
R297 T290 T291 arg1Of induction,of
R298 T293 T291 arg2Of death,of
R299 T293 T292 arg1Of death,apoptotic
R300 T279 T294 arg1Of induced,and
R301 T295 T294 arg2Of decreased,and
R302 T278 T295 arg1Of mutations,decreased
R303 T297 T295 arg2Of growth,decreased
R304 T297 T296 arg1Of growth,tumor
R305 T295 T298 arg1Of decreased,compared
R306 T299 T298 arg2Of with,compared
R307 T301 T299 arg2Of IgG1.121,with
R308 T301 T300 arg1Of IgG1.121,unmodified
R309 T304 T302 arg1Of modifications,The
R310 T304 T303 arg1Of modifications,“SELF”
R311 T304 T305 arg1Of modifications,that
R312 T309 T306 arg1Of increase,dramatically
R313 T306 T307 arg1Of dramatically,and
R314 T308 T307 arg2Of selectively,and
R315 T309 T308 arg1Of increase,selectively
R316 T304 T309 arg1Of modifications,increase
R317 T310 T309 arg2Of affinity,increase
R318 T310 T311 arg1Of affinity,for
R319 T312 T311 arg2Of FcγRIIb,for
R320 T304 T313 arg1Of modifications,have
R321 T316 T313 arg2Of used,have
R322 T316 T314 arg1Of used,also
R323 T304 T315 arg1Of modifications,been
R324 T316 T315 arg2Of used,been
R325 T304 T316 arg2Of modifications,used
R326 T318 T316 arg3Of enhance,used
R327 T318 T317 arg1Of enhance,to
R328 T304 T318 arg1Of modifications,enhance
R329 T301 T318 arg2Of IgG1.121,enhance
R330 T320 T319 arg1Of agonism,immune
R331 T299 T320 arg1Of with,agonism
R332 T320 T321 arg1Of agonism,in
R333 T324 T321 arg2Of model.122,in
R334 T324 T322 arg1Of model.122,an
R335 T324 T323 arg1Of model.122,anti‐OX40